BioAge Labs (BIOA) files 8-K: Q3 2025 results press release

BioAge Labs, Inc. furnished an 8‑K announcing it issued a press release with financial results for the third quarter ended September 30, 2025.

Rhea-AI Filing Summary

BioAge Labs, Inc. furnished an 8‑K announcing it issued a press release with financial results for the third quarter ended September 30, 2025. The disclosure is under Item 2.02 (Results of Operations and Financial Condition) and includes Exhibit 99.1 containing the press release. The company notes the information is furnished and not deemed filed under the Exchange Act or the Securities Act. BIOA common stock trades on the Nasdaq Global Select Market.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BIOA announce in this 8‑K?

BioAge Labs reported that it issued a press release with financial results for the third quarter ended September 30, 2025, furnished under Item 2.02.

Is the Item 2.02 information considered filed?

No. The company states the Item 2.02 information, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act or the Securities Act.

Which exhibit contains the press release for BIOA?

Exhibit 99.1 contains the press release dated November 6, 2025.

What is the period covered by BIOA’s results?

The press release covers the third quarter ended September 30, 2025.

Where is BIOA’s common stock listed and what is the ticker?

BIOA common stock is listed on the Nasdaq Global Select Market under the symbol BIOA.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/06/2025 - 04:50 PM Learn about SEC filing dates

0001709941false00017099412025-11-062025-11-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 06, 2025

BIOAGE LABS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-42279	47-4721157
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
5885 Hollis Street Suite 370
Emeryville, California				94608
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 510 806-1445

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.00001 Par Value Per Share		BIOA		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2025, BioAge Labs, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02, including Exhibit 99.1 attached to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release issued by BioAge Labs, Inc. dated November 6, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			BIOAGE LABS, INC.
Date:	November 6, 2025	By:	/s/ Dov Goldstein
			Dov Goldstein, M.D. Chief Financial Officer